Thermo Fisher Scientific Inc., the world leader in serving science has introduced the ToxInsight DILI Assay Cartridge, a groundbreaking new tool for assessing the liver toxicity risk of chemical compounds. It will help pharmaceutical companies improve their productivity by better assessing liver toxicity early in the drug development process, specifically reducing the risk of drug-induced liver injury (DILI) – the primary reason for post-market drug withdrawal. Designed to be used with the Thermo Scientific ToxInsight IVT image cytometry platform, the ToxInsight DILI Assay Cartridge identifies drug induced hepatotoxicity by simultaneous detection of multiplexed toxicity biomarkers in single cells. It includes all the reagents, assay protocols, analysis and data reporting capabilities to profile compounds for hepatotoxicity with high sensitivity and specificity. The cartridge has been extensively validated with a known hepatotoxic compound “truth-set” on a range of hepatic cell-lines, including rat and human primary hepatocytes.
